Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXRNASDAQ:EARSNASDAQ:EQNASDAQ:MTVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.85-7.2%$0.85$0.65▼$26.25$8.79M0.87634,856 shs531,163 shsEARSAuris Medical$0.30$2.88$0.73▼$6.60$3.43M1.173.10 million shs830,271 shsEQEquillium$0.35-10.0%$0.41$0.34▼$1.50$12.43M1.94432,505 shs1.02 million shsMTVAMetaVia$0.74-1.3%$0.84$0.63▼$5.30$14.48M0.18400,979 shs30,262 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-8.91%+7.50%+16.91%-38.67%-94.30%EARSAuris Medical0.00%0.00%0.00%0.00%-77.10%EQEquillium+0.13%+6.59%+1.15%-48.80%-45.64%MTVAMetaVia-0.33%+8.68%+15.38%-49.32%+74,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals2.4277 of 5 stars3.42.00.00.02.50.81.3EARSAuris MedicalN/AN/AN/AN/AN/AN/AN/AN/AEQEquillium3.181 of 5 stars3.25.00.00.03.31.70.6MTVAMetaVia2.4685 of 5 stars3.50.00.00.03.30.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.80Moderate Buy$54.506,281.73% UpsideEARSAuris Medical 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00762.07% UpsideMTVAMetaVia 3.00Buy$7.50913.51% UpsideCurrent Analyst Ratings BreakdownLatest EARS, EQ, MTVA, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/16/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.003/21/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$8.02 per shareN/AEARSAuris MedicalN/AN/AN/AN/A$1.57 per shareN/AEQEquillium$30.41M0.41N/AN/A$0.64 per share0.54MTVAMetaViaN/AN/AN/AN/A$3.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.000.68N/AN/A-51.69%-37.60%8/11/2025 (Estimated)EARSAuris Medical-$8.75MN/A0.00∞N/AN/AN/AN/AN/AEQEquillium-$13.34M-$0.39N/AN/AN/A-10.05%-20.68%-10.77%8/6/2025 (Estimated)MTVAMetaVia-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/13/2025 (Estimated)Latest EARS, EQ, MTVA, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEARSAuris MedicalN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.410.17EARSAuris MedicalN/A3.833.83EQEquilliumN/A3.043.04MTVAMetaViaN/A2.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%EARSAuris Medical6.03%EQEquillium27.05%MTVAMetaVia1.37%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%EARSAuris MedicalN/AEQEquillium31.60%MTVAMetaVia1.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2010.29 million7.55 millionOptionableEARSAuris Medical132,20011.42 millionN/ANot OptionableEQEquillium4035.72 million24.70 millionNot OptionableMTVAMetaVia819.56 million8.53 millionN/AEARS, EQ, MTVA, and CTXR HeadlinesRecent News About These CompaniesMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10 at 8:34 AM | financialpost.comMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10 at 8:31 AM | globenewswire.comMetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific SessionsJune 4, 2025 | prnewswire.comMTVA stock touches 52-week low at $0.64 amid market challengesJune 1, 2025 | uk.investing.comMetaVia Faces Nasdaq Delisting Notice for Low Stock PriceMay 30, 2025 | tipranks.comMTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…May 22, 2025 | finance.yahoo.comMetaVia Updates Corporate Presentation on DA-1726 ProgressMay 21, 2025 | tipranks.comMetaVia Inc.: MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 20, 2025 | finanznachrichten.deMetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comMetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesMay 9, 2025 | prnewswire.comMetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025May 7, 2025 | prnewswire.comMetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 studyApril 24, 2025 | markets.businessinsider.comMetaVia Advances Pipeline Targeting Obesity, Diabetes, and MASH; Phase 2a Data on DA-1241 to be Presented at EASL 2025April 23, 2025 | theglobeandmail.comMetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025April 23, 2025 | prnewswire.comMetaVia Reports Positive Phase 1 Trial ResultsApril 22, 2025 | tipranks.comMetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class PotentialApril 22, 2025 | prnewswire.comMetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing ...April 17, 2025 | seekingalpha.comMTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…April 17, 2025 | msn.comMetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and TolerabilityApril 15, 2025 | prnewswire.comMTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…March 31, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersIf the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyBy Chris Markoch | May 16, 2025View If the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?Top 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock WinsBy Chris Markoch | May 15, 2025View Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock WinsEARS, EQ, MTVA, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.85 -0.07 (-7.17%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Auris Medical NASDAQ:EARSAuris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.Equillium NASDAQ:EQ$0.35 -0.04 (-9.96%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.MetaVia NASDAQ:MTVA$0.74 -0.01 (-1.33%) As of 02:27 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
